

Red Cell Antibody Panels

Mark Dwight мsc сsci мивмs Advanced Specialist Biomedical Scientist RCI Filton

Caring Expert Quality







The Rules of the Game I

- BSH Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories (2012).
- Always do your best to exclude all <u>clinically significant</u> antibodies.
 - Excluding anti-Cw, -P1, -Kpa, -Lua, -Lea, Leb not *strictly* necessary if you don't have appropriate cells
- Don't forget your screening results!!!





The Rules of the Game II

- Antibody exclusions:
 - "...the presence of anti-Jka, anti-Jkb, anti-S, anti-s, anti-Fya and anti-Fyb should be excluded using red cells having homozygous expression of the relevant antigen..."
 - "...A single example only of each phenotype is sufficient for exclusion..."





The Rules of the Game III

- Antibody identification:
 - "...specificity should only be assigned when the plasma is reactive with at least two examples of reagent red cells expressing the antigen and non- reactive with at least two examples of reagent red cells lacking the antigen..."



The Enzyme Panel

- Papain most commonly used (from Papaya) *
- Papain enhances the reaction strength of
 - Rh system antibodies (anti-D, -C, -c, -E, -e, -Cw)
 - Kidd system antibodies (anti-Jka, -Jkb)
- Papain destroys some red cell antigens; so negative reactions will be observed with
 - MNS system antibodies (anti-M, -N, -S, -s)
 - Duffy system antibodies (anti-Fya, -Fyb)



* Ortho BioVue panels may use ficin



The Dosage Effect

- "Dosage" refers to the effect of seeing stronger reactions with homozygous antigen expression compared to heterozygous expression.
 - Eg. anti-Jka may react stronger with Jk(a+b-) cells than Jk(a+b+) cells





Gel IAT Grading in RCI







Cell	Rh	М	Ν	S	S	P1	Lu ^a	К	k	Kp ^a	Le ^a	Le ^b	Fya	Fy ^b	Jka	Jk ^b	
1	$R_1^w R_1$	0	+	0	+	5	0	+	+	0	0	+	0	+	0	+	0
2	R_1R_1	+	+	+	0	0	0	0	+	0	+	0	+	0	+	0	4
3	R_2R_2	0	+	0	+	3	0	0	+	0	+	0	0	+	+	0	0
4	r'r	+	0	+	0	3	0	0	+	0	0	+	0	+	+	0	0
5	r"r	+	0	+	0	0	0	0	+	0	0	+	+	0	0	+	4
6	rr	+	0	0	+	0	0	+	0	0	0	+	0	+	+	0	0
7	rr	+	0	+	0	0	0	+	+	0	0	0	ŧ	0	+	0	4
8	rr	0	+	0	+	2	0	0	+	+	0	+	+	0	+	0	4
9	rr	0	+	+	0	3	0	0	+	0	0	+	+	0	0	+	4
10	rr	+	0	Ŧ	0	3	+	0	+	0	+	0	0	+	0	+	0





Cell	Rh	М	Ν	S	S	P1	Lu ^a	К	k	Kpa	Le ^a	Le ^b	Fya	Fyb	Jka	Jk ^b	
1	$R_1^w R_1$	0	+	0	+	5	0	+	+	0	0	+	0	+	0	+	0
2	R_1R_1	+	+	+	0	0	0	0	+	0	+	0	+	0	+	0	4
3	R_2R_2	0	+	0	+	3	0	0	+	0	+	0	0	+	+	0	0
4	r'r	+	0	+	0	3	0	0	+	0	0	+	0	+	+	0	0
5	r"r	+	0	+	0	0	0	0	+	0	0	+	+	0	0	+	4
6	rr	+	0	0	+	0	0	+	0	0	0	+	0	+	+	0	0
7	rr	+	0	+	0	0	0	+	+	0	0	0	÷	0	+	0	4
8	rr	0	+	0	+	2	0	0	+	+	0	+	+	0	+	0	4
9	rr	0	+	+	0	3	0	0	+	0	0	+	+	0	0	+	4
10	rr	+	0	Ŧ	0	3	+	0	+	0	+	0	0	+	0	+	0





Cell	Rh	М	N	S	S	P1	Luª	K	k	Kpa	Lea	Le ^b	Fya	Fyb	Jka	Jk ^b	
1	$R_1 W R_1$	0	\checkmark	0	+	ц	0	+	+	0	0	1	0	+	0	1	0
2	R_1R_1	+	+	+	0	0	0	0	+	0	+	0	+	0	+	0	4
3	P_2R_2	0	+	0	+	3	0	0	ł	0	┝	0	0	+	┝	0	0
4	r'r	1	0	×	0	3	0	0	+	0	0	+	0	+	+	0	0
5	r"r	+	0	+	0	0	0	0	+	0	0	+	+	0	0	+	4
6	rr	+	0	0	+	0	0	+	0	0	0	+	0	+	+	0	0
7	rr	+	0	+	0	0	0	+	+	0	0	0	+	0	+	0	4
8	rr	0	+	0	+	2	0	0	+	+	0	+	+	0	+	0	4
9	rr	0	+	+	0	3	0	0	+	0	0	+	+	0	0	+	4
10	rr	+	0	+	0	3	ł	0	+	0	+	0	0	+	0	+	0





Your Turn!





Panel Sheet Exercise

- Key
 - "IAT" = BioRad Gel IAT results
 - "ENZ" = BioRad Enzyme results (papainised cells)
- Effect of Papain (enzyme panel)
 - Enhances reactions with anti-D, -C, -c, -E, -e, -C^w, -Jka, -Jkb
 - Destroys M, N, S, s, Fya, Fyb antigens
- NOTE: Case E has two panel sheets!





Answers





Case A: Panel 1

	Rh	С	D	E	с	е	Cw	М	Ν	S	s	P1	Lu ^a	K	k	Kp ^a	Le ^a	Le ^b	Fy ^a	Fy ^b	Jk ^a	Jk ^b	Other	1AI	ash			
1	$R_1^W R_1$	+	+	0	0	+	+	+	+	0	+	4	0	+	+	0	+	0	0	+	+	0		0	0			
2	R ₁ R ₁	+	+	0	0	+	0	+	0	+	0	3	0	0	+	0	0	+	+	0	0	+		0	0			
3	R_2R_2	0	+	+	+	0	0	0	+	0	+	2	0	0	+	+	0	+	+	0	0	+		3	5			
4	r'r	+	0	0	+	+	0	0	+	0	+	2	0	0	+	0	+	0	0	+	0	÷	Kna-	0	0			
5	r"r	0	0	+	+	+	0	+	0	+	0	1	0	0	+	0	+	0	0	+	+	0		4	5			
6	rr	0	0	0	+	+	0	+	0	+	0	4	0	+	0	0	0	+	+	0	0	+		0	0			
7	rr	0	0	0	+	+	0	0	+	0	+	1	0	+	+	0	0	+	+	w	0	+		0	0			
8	rr	0	0	0	+	+	0	+	+	0	+	0	0	0	+	+	÷	0	+	0	+	0		0	0			
9	rr	0	0	0	+	+	0	+	0	0	+	0	+	0	+	0	0	+	0	+	0	+		0	0			
10	rr	0	0	0	+	+	0	0	+	+	0	3	0	0	+	0	0	+	0	+	+	0		0	0			
																							AUTO	0	1			
R	Reagent			T						1					DAT	Profile	A	nti-IgG		IgA		IgM	C3c		C	3d	Ctrl	
l	_ot No.														R	esult												





Case A

	Rh	С	D	E	с	е	Cw	М	Ν	S	s	P1	Lu ^a	K	k	Kp ^a	Le ^a	Le ^b	Fy ^a	Fy ^b	Jk ^a	Jk ^b	Other	1RI	(ASL			
1	$R_1^W R_1$	+	+	0	0	+	+	+	+	0	+	4	0	+	+	0	+	0	0	+	+	0		0	0			
2	R ₁ R ₁	+	+	0	0	+	0	+	0	+	0	3	0	0	+	0	0	+	+	0	0	+		0	0			
3	R_2R_2	0	+	+	+	0	0	0	+	0	+	2	0	0	+	+	0	+	+	0	0	+		3	5			
4	r'r	+	0	0	+	+	0	0	+	0	+	2	0	0	+	0	+	0	0	+	0	÷	Kna-	0	0			
5	r"r	0	0	+	+	+	0	÷	0	+	0	1	0	0	+	0	+	0	0	+	+	0		4	5			
6	rr	0	0	0	+	+	0	+	0	+	0	4	0	+	0	0	0	+	+	0	0	+		0	0			
7	rr	0	0	0	+	+	0	0	+	0	+	1	0	+	+	0	0	+	+	w	0	+		0	0			
8	rr	0	0	0	+	+	0	+	+	0	+	0	0	0	+	+	÷	0	+	0	+	0		0	0			
9	rr	0	0	0	+	+	0	+	0	0	+	0	+	0	+	0	0	+	0	+	0	+		0	0			
10	rr	0	0	0	+	+	0	0	+	+	0	3	0	0	+	0	0	+	0	+	+	0		0	0			
																							AUTO	0	1			
																									20			
R	Reagent		1	T	-	1	1			1			1		DAT	Profile	A	nti-IgG		IgA		IgM	C3c		C	3d	Ctrl	
L	Lot No.														R	esult												





Case B: Panel 1

	Rh	С	D	E	с	e	Cw	M	N	S	s	P1	Lu ^a	K	k	Kp ^a	Le ^a	Le ^b	Fy ^a	Fy ^b	Jk ^a	Jk ^b	Other	IAT	EN2			
1	$R_1^W R_1$	+	+	0	0	+	+	+	+	0	+	4	0	+	+	0	+	0	0	+	+	0		0	0			
2	R ₁ R ₁	+	+	0	0	+	0	+	0	+	0	3	0	0	+	0	0	+	+	0	0	+		3	0			
3	R_2R_2	0	+	+	+	0	0	0	+	0	+	2	0	0	+	+	0	+	+	0	0	+		3	0			
4	r'r	+	0	0	+	+	0	0	+	0	+	2	0	0	+	0	+	0	0	+	0	+	Kna-	0	0			
5	r''r	0	0	+	+	+	0	+	0	+	0	1	0	0	+	0	+	0	0	+	+	0		0	0			
6	rr	0	0	0	+	+	0	+	0	+	0	4	0	+	0	0	0	+	+	0	0	+		3	0			
7	rr	0	0	0	+	+	0	0	+	0	+	1	0	+	+	0	0	+	+	w	0	+		3	0			
8	rr	0	0	0	+	+	0	+	+	0	+	0	0	0	+	+	+	0	+	0	+	0		3	0			
9	rr	0	0	0	+	+	0	+	0	0	+	0	+	0	+	0	0	+	0	+	0	+		0	0			
10	rr	0	0	0	+	+	0	0	+	+	0	3	0	0	+	0	0	+	0	+	+	0		0	0			
																							AUTO	0	/			_
					-																			-				
R	leagent			T	1		1	1	1		1	L	1		DAT	Profile	Ar	nti-IgG		IgA	-	IgM	C3c		C	3d	Ctrl	
L	_ot No.														R	esult												





Case B

	Rh	С	D	Е	с	е	Cw	M	N	S	s	P1	Lu ^a	K	k	Kp ^a	Le ^a	Le ^b	Fy ^a	Fy ^b	Jk ^a	Jk ^b	Other	IAT	EN2	
1	R ₁ ^W R ₁	+	+	0	0	+	+	+	+	0	+	4	0	+	+	0	+	0	0	+	+	0		0	0	
2	R ₁ R ₁	+	+	0	0	+	0	+	0	+	0	3	0	0	+	0	0	+	+	0	0	+		3	0	
3	R_2R_2	0	+	+	+	0	0	0	+	0	+	2	0	0	+	+	0	+	+	0	0	+		3	0	
4	r'r	+	0	0	+	+	0	0	+	0	+	2	0	0	+	0	+	0	0	+	0	+	Kna-	0	0	
5	r"r	0	0	+	+	+	0	+	0	+	0	1	0	0	+	0	+	0	0	+	+	0		0	0	
6	rr	0	0	0	+	+	0	+	0	+	0	4	0	+	0	0	0	+	+	0	0	+		3	0	
7	rr	0	0	0	+	+	0	0	+	0	+	1	0	+	+	0	0	+	+	w	0	+		3	0	
8	rr	0	0	0	+	+	0	+	+	0	+	0	0	0	+	+	+	0	+	0	+	0		3	0	
9	rr	0	0	0	+	+	0	+	0	0	+	0	+	0	+	0	0	+	0	+	0	+		0	0	
10	rr	0	0	0	+	+	0	0	+	+	0	3	0	0	+	0	0	+	0	+	+	0		0	0	
																							AUTO	0	/	
		-		-															-		-			-		 _
R	eagent			1											DAT	Profile	Ar	nti-IgG		lgA		lgM	C3c		C3d	Ctrl
L	ot No.														R	esult						_				





Case C: Panel 1

Instru	ctions for use	can	be fo	ound	at h	ttp://\	www.b	lood.c	co.uk/r	reager	nts																15	
	Rh	С	D	E	с	e	Cw	M	N	S	s	P1	Lu ^a	к	k	Kp ^a	Le ^a	Le ^b	Fy ^a	Fy ^b	Jk ^a	Jk ^b	Other	ART	02	197	ide	
1	R ₁ ^W R ₁	+	+	0	0	+	+	+	+	0	+	4	0	+	+	0	+	0	0	+	+	0		0	0	1		
2	R ₁ R ₁	+	+	0	0	+	0	+	0	+	0	3	0	0	+	0	0	+	+	0	0	+		0	0	0	>	
3	R_2R_2	0	+	+	+	0	0	0	+	0	+	2	0	0	+	+	0	+	+	0	0	+		0	0	C	>	
4	r'r	+	0	0	+	+	0	0	+	0	+	2	0	0	+	0	+	0	0	+	0	+	Kna-	0	0	0	C	
5	r"r	0	0	+	+	+	0	+	0	+	0	1	0	0	+	0	+	0	0	+	+	0		0	0	1	t	
6	rr	0	0	0	+	+	0	+	0	+	0	4	0	+	0	0	0	+	+	0	0	+		0	0	0	2	
7	rr	0	0	0	+	+	0	0	+	0	+	1	0	+	+	0	0	+	+	w	0	+		0	0	0	>	
8	rr	0	0	0	+	+	0	+	+	0	+	0	0	0	+	+	+	0	+	0	+	0		0	0	1		
9	rr	0	0	0	+	+	0	+	0	0	+	0	+	0	+	0	0	+	0	+	0	+		0	0	C	2	
10	rr	0	0	0	+	+	0	0	+	+	0	3	0	0	+	0	0	+	0	+	+	0		0	0		1	
																							AUTO	3	1	/	/	
																					1							_
						-								1	1										1			
F	Reagent					-									DAT	Profile	A	nti-IgG	i	IgA		IgM	C3c		C	3d	Ct	rl
	Lot No.														R	esult		3mf		0		0	0		5	0	0	





.5

Case C

Instructions for	use can	be found at	http://www.	blood.co.uk/reagents
------------------	---------	-------------	-------------	----------------------

	Rh	С	D	E	с	e	Cw	M	N	S	s	P1	Lu ^a	к	k	Kp ^a	Le ^a	Le ^b	Fy ^a	Fy ^b	Jk ^a	Jk ^b	Other	, AT	02	6.0	ide	
1	$R_1^W R_1$	+	÷	0	0	+	+	+	+	0	+	4	0	+	+	0	+	0	0	+	÷	0		0	0			
2	R ₁ R ₁	+	+	0	0	+	0	+	0	+	0	3	0	0	+	0	0	+	+	0	0	+		0	0	(
3	R_2R_2	0	+	+	+	0	0	0	+	0	+	2	0	0	+	+	0	+	+	0	0	+		0	0	(
4	r'r	+	0	0	+	+	0	0	+	0	+	2	0	0	+	0	+	0	0	+	0	+	Kna-	0	0		C	
5	r"r	0	0	+	+	+	0	+	0	+	0	1	0	0	+	0	+	0	0	+	+	0		0	0		t	
6	rr	0	0	0	+	+	0	+	0	+	0	4	0	+	0	0	0	+	+	0	0	+		0	0	0	C	
7	rr	0	0	0	+	+	0	0	+	0	+	1	0	+	+	0	0	+	+	w	0	+		0	0	(D	
8	rr	0	0	0	+	+	0	+	+	0	+	0	0	0	+	+	+	0	+	0	+	0		0	0			
9	rr	0	0	0	+	+	0	+	0	0	+	0	+	0	+	0	0	+	0	+	0	+		0	0	(2	
10	rr	0	0	0	+	+	0	0	+	+	0	3	0	0	+	0	0	+	0	+	+	0		0	0			
																							AUTO	3	1		/	
																									1			
R	leagent														DAT	Profile	A	nti-IgG		IgA		IgM	C3c		C	3d		Ctrl
l	_ot No.														R	esult		3mf		0		0	0		0	>	<	2





Case D: Panel 1

	Rh	С	D	E	с	e	Cw	м	N	s	s	P1	Lu ^a	к	k	Kp ^a	Le ^a	Le ^b	Fy ^a	Fy ^b	Jk ^a	Jk ^b	Other	IAT	ENZ			
1	R ₁ ^W R ₁	+	+	0	0	+	+	+	+	0	+	4	0	+	+	0	+	0	0	+	+	0		3	5			
2	R ₁ R ₁	+	+	0	0	+	0	+	0	+	0	3	0	0	+	0	0	+	+	0	0	+		3	5			
3	R ₂ R ₂	0	+	+	+	0	0	0	+	0	+	2	0	0	+	+	0	+	+	0	0	+		3	0			
4	r'r	+	0	0	+	+	0	0	+	0	+	2	0	0	+	0	+	0	0	+	0	+	Kna-	3	5			
5	r"r	0	0	+	+	+	0	+	0	+	0	1	0	0	+	0	+	0	0	+	+	0		0	0			
6	rr	0	0	0	+	+	0	+	0	+	0	4	0	+	0	0	0	+	+	0	0	+		0	0			
7	rr	0	0	0	+	+	0	0	+	0	+	1	0	+	+	0	0	+	+	w	0	+		3	0			
8	rr	0	0	0	+	+	0	+	+	0	+	0	0	0	+	+	+	0	+	0	+	0		3	0			
9	rr	0	0	0	+	+	0	+	0	0	+	0	+	0	+	0	0	+	0	+	0	+		3	0		-	
10	rr	0	0	0	+	+	0	0	+	+	0	3	0	0	+	0	0	+	0	+	+	0		0	0			
		1																					AUTO	0	1			
		1		1		1																			- 10			
R	eagent			1		-	1		1		1		1		DAT	Profile	A	nti-IgG		IgA		IgM	C3c		C	3d	Ctrl	
l	ot No.														R	esult												





Case D

	Rh	С	D	E	с	e	Cw	м	N	S	s	P1	Lu ^a	K	k	Kp ^a	Le ^a	Le ^b	Fy ^a	Fy ^b	Jk ^a	Jk ^b	Other	IAT	ENZ		
1	R ₁ ^W R ₁	+	+	0	0	+	+	+	+	0	+	4	0	+	+	0	+	0	0	+	+	0		3	5		
2	R_1R_1	+	+	0	0	+	0	+	0	+	0	3	0	0	+	0	0	+	+	0	0	+		3	5		
3	R_2R_2	0	+	+	+	0	0	0	+	0	+	2	0	0	-	+	0	+	+	0	0	+		3	0		
4	r'r	+	0	0	+	+	0	0	+	0	+	2	0	0	+	0	+	0	0	+	0	+	Kna-	3	5		
5	r"r	0	0	+	+	+	0	+	0	+	0	1	0	0	+	0	+	0	0	+	+	0		0	0		
6	rr	0	0	0	+	+	0	+	0	+	0	4	0	+	0	0	0	+	+	0	0	+		0	0		
7	rr	0	0	0	+	+	0	0	+	0	+	1	0	+	+	0	0	+	+	w	0	+		3	0		
8	rr	0	0	0	+	+	0	+	+	0	+	0	0	0	+	+	+	0	+	0	+	0		3	0		
9	rr	0	0	0	+	+	0	+	0	0	+	0	+	0	+	0	0	+	0	+	0	+		3	0		
10	rr	0	0	0	+	+	0	0	+	+	0	3	0	0	+	0	0	+	0	+	+	0		0	0		
																							AUTO	0	1		
																									1		
R	eagent			1	-						1		1		DAT	Profile	A	nti-IgG		IgA		IgM	C3c		C	3d	Ctrl
L	ot No.														R	esult											





Case E: Panel 1

	Rh	C	D	E	c	e	C*	м	N	S	s	P1	Luª	к	k	Kp ^a	Lea	Le ^b	Fya	Fyb	Jkª	Jkb	Other	K	2		T	
1	R1WR1	+	+	0	0	+	+	0	+	0	+	2	0	0	+	0	+	0	+	0	+	0	Cob+	0	0		+	+
2	R ₁ R ₁	+	+	0	0	+	0	+	0	+	0	0	0	+	+	0	0	+	0	+	0	+		3	õ		-	+
3	R ₂ R ₂	0	+	+	+	0	0	0	+	0	+	2	0	0	+	0	0	0	+	0	+	0	HLA +	5	5	\vdash	+	+
4	r'r	+	0	0	+	+	0	+	0	0	+	0	0	0	+	0	0	+	0	+	+	0		5	5	\vdash	+	+
5	r"r	0	0	+	+	+	0	+	0	+	0	3	0	0	+	0	0	+	0	+	0	+		C	5	\vdash	+	+
6	rr	0	0	0	+	+	0	+	+	0	+	4	0	+	0	0	0	+	0	+	+	0		5	5	\vdash	+	-
7	rr	0	0	0	+	+	0	0	+	0	+	4	0	+	+	0	+	0	+	0	0	+		C	3	\vdash	+	-
8	rr	0	0	0	+	+	0	0	+	0	+	4	+	0	+	+	+	0	0	+	0	+		5	0		+	-
9	rr	0	0	0	÷	+	0	0	+	+	0	0	0	0	+	0	0	+	w	0	+	0		5	5		+	+
10	rr	0	0	0	+	+	0	+	0	+	0	4	+	0	+	0	+	0	+	0	+	0	Cob+	5	5		+	+
																1							Auto	0	/			-
									-	_	_	_					-	_		_	_							
R	eagent		_	T											DAT	Profile	Ant	i-lgG		lgA		lgM	C3c	4	C3			trl
L	ot No.		_												Re	sult								1			-	_





Case E: Reference Panel 1

	Rh	С	D	Е	с	е	Cw	М	Ν	s	s	P1	Lu ^a	к	k	Kp ^a	Le ^a	Le ^b	Fy ^a	Fy ^b	Jk ^a	Jk ^b	Other	PAL	-		
1	R1wR1	+	+	0	0	+	+	0	+	0	+	0	0	0	+	0	+	0	0	+	0	+	Bgb+	0			
2	R1wR1	+	+	0	0	+	+	+	0	+	0	0	0	0	+	0	0	+	+	0	+	0	Cob+	3			
3	R1Rz	+	+	+	0	+	0	+	+	0	+	0	0	0	+	0	0	+	0	+	0	+		0		_	
4	R1Rz	+	+	+	0	+	0	0	+	0	+	4	0	0	+	0	0	+	÷	0	+	0		0			
5	Ror	0	+	0	÷	+	0	+	0	0	+	4	0	0	+	0	0	+	0	0	+	0	Dob- Goa+	5			
6	R1R1	+	+	0	0	+	0	0	+	+	0	1	0	+	0	0	0	0	w	0	0	+		0			
7	R1R1	+	+	0	0	+	0	+	0	0	+	0	0	+	+	0	0	+	0	+	+	0		3			\top
8	R1R1	+	+	0	0	+	0	0	+	0	+	2	0	0	+	+	0	+	+	0	+	0		0		1	1
9	R1R1	+	+	0	0	+	0	+	0	+	0	3	0	0	+	0	+	0	0	+	0	+		3			1
10	R1R1	+	+	0	0	+	0	+	+	0	+	3	+	0	+	0	0	+	+	0	0	+	Cob+	0			
																							AUCTO	0			
																									_		-
R	eagent														AT Pro	ofile	An	ti-lgG		IgA		IgM	C3c	c	3d	Ct	rl
L	ot No.														Resu	lt											





Case E

	Rh	С	D	E	с	е	Cw	М	N	S	s	P1	Lu ^a	к	k	Kp ^a	Le ^a	Le ^b	Fy ^a	Fy^b	Jk ^a	Jk ^b	Other	PAL	2	
1	R1wR1	+	+	0	0	+	+	0	+	0	+	0	0	0	+	0	+	0	0	÷	0	+	Bgb+	0		
2	R1wR1	+	+	0	0	+	+	+	0	+	0	0	0	0	+	0	0	+	+	0	+	0	Cob+	3		
3	R1Rz	+	+	+	0	+	0	+	+	0	+	0	0	0	+	0	0	+	0	+	0	+		0		
4	R1Rz	+	+	+	0	+	0	0	+	0	+	4	0	0	+	0	0	+	+	0	+	0		0		
5	Ror	0	+	0	+	+	0	+	0	0	+	4	0	0	+	0	0	+	0	0	+	0	Dob- Goa+	5		
6	R1R1	+	+	0	0	+	0	0	+	+	0	1	0	+	0	0	0	0	w	0	0	+		0		
7	R1R1	+	+	0	0	+	0	+	0	0	+	0	0	+	+	0	0	+	0	+	+	0		3		
8	R1R1	+	+	0	0	+	0	0	+	0	+	2	0	0	+	+	0	+	+	0	+	0		0		
9	R1R1	+	+	0	0	+	0	+	0	+	0	3	0	0	+	0	+	0	0	+	0	+		3		
10	R1R1	+	+	0	0	+	0	+	+	0	+	3	+	0	+	0	0	+	+	0	0	+	Cob+	0		
																	_						AUTO	0		
						-																				
R	leagent														AT Pro	ofile	Ant	ti-lgG		IgA		IgM	C3c	0	3d	Ctrl
L	_ot No.														Resu	lt					-					





Case F: Panel 1

	Rh	C	D	E	c	e	C.	м	N	S	8	P1	Luª	к	k	Kp ^a	Leª	Leb	Fy*	Fyb	Jka	Jk ^b	Other	x	2	
1	R1WR1	+	+	0	0	+	+	+	0	+	0	0	0	+	+/	0	+	0	0	+	0	+		Z	<	
2	R ₁ R ₁	+	+	0	0	+	0	0	+	0	+	0	0	0	+	0	0	+	+	0	+	0		2	c	-+-+
3	R ₂ R ₂	0	+	+	+	0	0	+	0	+	0	2	0	0	+	0	+	0	+	0	0	+	HLA+	2	5	
4	r'r	+	0	0	+	+	0	0	+	0	+	0	0	0	+	0	+	0	+	+	+	0		2	2	
5	r"r	0	0	+	+	+	0	0	+	0	+	4	+	0	+	0	0	+	0	+	+	0		2	2	
6	rr	0	0	0	+	+	0	+	0	+	0	1	0	+	0	0	0	+	+	0	+	0		3	2	
7	rr	0	0	0	+	+	0	0	+	0	+	3	0	+	+	0	+	0	0	+	+	0	Cob+	2	5	
8	rr	0	0	0	+	+	0	0	+	0	+	0	0	0	+	+	0	+	+	0	+	0		3	e	
9	rr	0	0	0	+	+	0	+	0	0	+	2	+	0	+	0	0	+	0	+	0	+		2	5	
10	rr	0	0	0	+	+	0	0	+	+	0	3	0	0	+	0	+	0	+	0	0	+	Cob+	3	5	++
																5							Auto	3	-	
													_													
P	anani			\downarrow																						
TSE.	agent			+					_						DAT	Profile	An	ti-IgG		IgA		IgM	C3c		C3d	Ctrl





Case F

Instru	ctions for use	can	be f	ound	at h	ttp://	www.b	lood.	co.uk/	reager	nts					1										
	Rh	С	D	E	c		C,	м	N	S	8	P1	Luª	ĸ	k	Kpa	Leª	Leb	Fy*	Fy ^b	Jka	Jk ^b	Other	s.	02	
1	R ₁ ^W R ₁	+	+	0	0	+	+	+	0	+	0	0	0	+	+/	0	+	0	0	+	0	+		2	5	
2	R ₁ R ₁	+	+	0	0	+	0	0	+	0	+	0	0	0	+	0	0	+	+	0	+	0		3	<	
3	R ₂ R ₂	0	+	+	+	0	0	+	0	+	0	2	0	0	+	0	+	0	+	0	0	+	HLA+	3	5	
4	r'r	+	0	0	+	+	0	0	+	0	+	0	0	0	+	0	+	0	+	+	+	0		3	5	
5	r"r	0	0	+	+	+	0	0	+	0	+	4	+	0	+	0	0	+	0	+	+	0		3	5	
6	rr	0	0	0	+	+	0	+	0	+	0	1	0	+	0	0	0	+	+	0	+	0		3	2	
7	rr	0	0	0	+	+	0	0	+	0	+	3	0	+	+	0	+	0	0	+	+	0	Cob+	3	5	
8	rr	0	0	0	+	+	0	0	+	0	+	0	0	0	+	+	0	+	+	0	+	0		3	e l	
9	rr	0	0	0	+	+	0	+	0	0	+	2	+	0	+	0	0	+	0	+	0	+		2	5	
10	rr	0	0	0	+	+	0	0	+	+	0	3	0	0	+	0	+	0	+	0	0	+	Cob+	3	5	
																1							Auto	3	-	
		_	_			_	_																			
R	eagent														DAT	Profile	An	ti-laG		laA		IaM	C3c	4	C3d	CM
L	ot No.														Re	sult		3		0	-	O	0	+	0	0

Refer to RCI?!



Red Cell Immunohaematology

Mark Dwight мsc сsci мивмs Advanced Specialist Biomedical Scientist RCI Filton

Caring Expert Quality



The RCI Laboratories



Red Cell Immunohaematology

- Reference laboratories supporting hospital blood banks in England.
- RCI laboratories at NHSBT centers in
 - Newcastle
 - Leeds
 - Sheffield
 - Liverpool
 - Birmingham
 - Bristol (Filton)
 - London (Colindale and Tooting)





RCI Services

- Blood Grouping Anomalies
- Antibody Investigations
 - Complex antibody investigations
 - Crossmatching
- Antenatal Reference Services
 - Titrations / Quantitations (anti-D, anti-c)
- Fetal-Maternal Haemorrhage
- Transfusion Reaction Investigations





Antibody Investigations





Panels and Cells

- Panel cells from NHSBT reagents
 - Panel 1 and 2
 - Reference Panel 1 (R1R1, for anti-c)
 - Reference Panel 2 (R2R2, for anti-e)
- Rare cells from selected donors
 - From Testing / Rare Cell Exchange Scheme
 - Frozen Cell Bank
 - High freq negatives, eg. K+k-, U-, Vel-
 - Low freq positives, eg. Wr(a+), Js(a+), Di(a+)





Serological Techniques

- A variety of techniques are employed
 - BioRad gel IAT
 - BioRad enzyme IAT
 - LISS Tube IAT
 - Saline (direct agglutination)
 - Capture-R (Immucor)
 - BioVue IAT (Ortho)
- Vary temperature, incubation times, etc







Adsorptions & Elutions

- DAT performed if auto control positive
 - Monospecific anti-IgG, -IgM, -IgA, -C3d, -C3c
- Autoantibodies can be removed by
 - Autoadsorptions: ZZAP-treated own cells
 - Alloadsorptions: paired reagent cells
- Elutions may be used to ascertain specificity of antibody coating red cells
 - Transfusion Reactions
 - Haemolytic Disease of the Fetus & Newborn





Antibody Neutralisation

- "Nuisance" antibodies can be inhibited or neutralised to reveal any underlying alloantibodies
- Chido-Rogers antibodies
 - Target C4 complement proteins
 - Neutralised by the addition of excess complement (AB serum)
- Knops-McCoy antibodies
 - Target CR1 molecule on red cells
 - Neutralised by the addition of recombinant KNIR reagent





Phenotyping & Genotyping

- Allo or autoantibody?
- Phenotyping
 - Serological testing using antisera
 - Phenotyping cannot be performed if the patient has had a recent transfusion.
- Genotyping
 - DNA Sequencing
 - Consider in: transfusion-dependent patients (eg. sickle cell), patients with multiple antibodies, before starting treatments, eg. Daratumumab





Drug-Related Panreactivity

- In some monoclonal antibody therapies the *drug* causes positive reactions vs all cells
- Daratumumab (Darzalex)
 - Anti-CD38 used in Multiple Myeloma
 - Drug action inhibited using DTT
- Camellia
 - Anti-CD47 used in AML
 - Genotype-matched blood issued





Tertiary Referral

- The International Blood Group Reference Laboratory (IBGRL) is located at NHSBT Filton
 - Samples may be referred to IBGRL from RCI if antibody specificity cannot be ascertained
 - IBGRL receive samples from all over the World.
- The National Frozen Blood Bank is located at NHSBT Liverpool
 - Rare donors are identified by Testing and red cell units frozen
 - Rare, frozen blood can be requested when required
 - eg. Bombay phenotype (with anti-H)





Thank you!



